The application proposes to provide a research base of investigators who will participate in the timely evaluation of novel therapeutic agents for pediatric cancer in a Phase I setting coordinated through the Childrens Cancer Group (CCG). Although current anti-cancer therapies have cured the majority of children with cancer, a substantial portion of such patients fail to achieve remission or demonstrate progression of disease once initially controlled. Therefore, identification and testing of new cytotoxic, biologic and immunotherapeutic agents will provide novel treatments which will result in continued improvements in the long term outcome of children with cancer. Patients entered on such trials frequently represent a heterogeneous group with respect to clinical characteristics and diagnoses. A large data base of study entrants will be available to identify specific factors which, if measured prior to entry, may predispose the inevaluability: the recognition of such factors will result in the design of more efficient Phase I trials. The centralized nature of this clinical trial group proposes to provide a central resource for monitoring patient entry and requesting follow-up data at specified intervals, to provide a central resource for computerization of clinical and biologic data and to provide statistical expertise in the design and analysis of data arising from such efforts. In addition, the provision of centralized pharmacology laboratory facilities as well as specific reference laboratories, not related to clinical care issues and not available at all institutions, will provide pharmacokinetic and pharmacodynamic support for the identification of appropriate treatment plans for individual patients. The group proposes to conduct pharmacologically-guided, dose escalation Phase I clinical trials when pre-clinical pharmacologic data are available and when such studies are warranted in the pediatric population. Precise pharmacological profiles will aid in efficiently identifying the appropriate dose to evaluate in Phase II and Phase III settings. Appropriate correlative biologic studies to determine optimum biologic effect in the case of bio-and immunotherapeutic agents will be undertaken. Selected performance at such institutions is considered appropriate for the safe and efficient conduct of such studies. Rigorous quality control and performance monitoring and sound scientific rationale in the design of studies will assure the efficient identification of tolerable and biologically effective doses for timely incorporation into wider scale pediatric clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA057746-08
Application #
2894968
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Program Officer
Smith, Malcolm M
Project Start
1992-09-30
Project End
2001-08-31
Budget Start
1999-09-01
Budget End
2000-08-31
Support Year
8
Fiscal Year
1999
Total Cost
Indirect Cost
Name
National Childhood Cancer Foundation
Department
Type
DUNS #
624124301
City
Arcadia
State
CA
Country
United States
Zip Code
91006
Children's Oncology Group (CCG 09709); Villablanca, Judith G; Krailo, Mark D et al. (2006) Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 24:3423-30
Sondel, P M (1999) Post-transplant immunotherapy designed to prevent cancer recurrence. Pediatr Transplant 3 Suppl 1:96-101
Seibel, N L; Blaney, S M; O'Brien, M et al. (1999) Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin Cancer Res 5:733-7
Ek, O; Reaman, G H; Crankshaw, D L et al. (1998) Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia. Leuk Lymphoma 28:509-14
Frost, J D; Hank, J A; Reaman, G H et al. (1997) A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 80:317-33
Cairo, M S (1995) The use of ifosfamide, carboplatin, and etoposide in children with solid tumors. Semin Oncol 22:23-7
Bauer, M; Reaman, G H; Hank, J A et al. (1995) A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer 75:2959-65